- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2025 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Latest Conference Articles
EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer
February 16th 2025, 3:00pm
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Outcomes May Be Consistent With Fotivda Alone or With Opdivo in Kidney Cancer Subset
February 15th 2025, 10:52pm
Patient-reported outcomes were similar for Fotivda with or without Opdivo in advanced clear cell RCC.
Opdivo Plus Cabometyx Safe, Effective in Advanced Renal Cell Carcinoma
February 15th 2025, 10:36pm
Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.
Cabometyx Combo Maintains Progression-Free Survival Benefit in Advanced RCC
February 15th 2025, 8:54pm
Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with Cabometyx, Opdivo and Yervoy.
Antitumor Activity Elicited in ccRCC Following Lenvima/Welireg Treatment
February 15th 2025, 8:43pm
Among patients with clear cell renal cell carcinoma, improved responses were observed with Lenvima plus Welireg versus Keytruda plus Lenvima.
FDA-Approved Fotivda Dose More Effective Than Reduced Dose in RCC
February 15th 2025, 8:04pm
Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.
Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer
February 15th 2025, 6:00pm
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Padcev Significantly Improves OS in Real-World Urothelial Carcinoma
February 15th 2025, 5:25pm
Among patients in the real world with unresectable or metastatic urothelial carcinoma, Padcev significantly improved overall survival outcomes.
Understanding How One Must Interpret PSA Levels in Prostate Cancer
February 14th 2025, 10:00pm
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression.
Padcev Plus Keytruda Shows Promise for Upper Tract Urothelial Carcinoma Lesions
February 14th 2025, 9:32pm
Results from a small retrospective analysis of patients with upper tract urothelial carcinoma lesions were shared at the 2025 ASCO Genitourinary Cancers Symposium.